Aesica Recruits Operations Director in Formulated Products Business Unit
News Feb 05, 2013
Aesica has appointed Jarrett Palmer as Operations Director of its formulated products business unit business.
Palmer has accumulated over 15 years’ experience in senior leadership positions and has managed facilities for global CMOs including Catalent Pharma Solutions and Piramal Healthcare.
Based at Aesica headquarters in Newcastle (UK), Palmer will report to Chris Gowland , Managing Director of Formulated Products.
Operations at the Queenborough facility (UK) and recently acquired sites in Europe - including Monheim and Zwickau (Germany) and Pianezza (Italy) - will be managed by Palmer who will coordinate operational activities around the company’s commercial scale manufacturing, packaging and distribution activities.
Pivotal to this new role is the continued sustainable growth of Aesica, which includes continuous improvement to drive manufacturing efficiency and managing growing demand for potent manufacturing from the company’s UK base.
“We are delighted to have Jarrett Palmer join Aesica as Operations Director. He brings significant experience with a long and established track record of managing sites for global CMOs. Jarrett’s role is central to the maintenance of high standards at our FDA approved commercial scale manufacturing sites. He will be critical to the acquisition process and will support senior management in identifying global acquisition targets and transitioning new sites in line with our exacting efficiency and quality standards”, commented Chris Gowland Managing Director of Formulated Products at Aesica.
“Aesica is one of the most exciting names in contract manufacturing at the moment”, added Palmer on his decision to join the company. “It has big plans for growth which will significantly increase its global footprint and its manufacturing and packaging capacity at commercial scale, which is what the market has a great demand for. The prospect of being at the heart of this dynamic business is what attracted me to Aesica. My goal is to ensure that at every step, we optimize our internal infrastructure so that our customers enjoy responsiveness and efficiency in all interaction with us.”
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018